Home / Health / Unpaid Carers Face Hidden Costs of Dementia Drugs
Unpaid Carers Face Hidden Costs of Dementia Drugs
3 Apr
Summary
- Campaigner highlights hidden costs for families of dementia patients.
- NHS spending watchdog reexamines Alzheimer's drug funding decision.
- Impact on unpaid carers is a key element under review.
Decisions regarding funding for Alzheimer's drugs must now account for the "hidden costs" incurred by families, according to a dedicated campaigner. These costs often fall upon relatives left to manage the challenges associated with the disease. The National Health Service's spending watchdog is currently undertaking a review of its prior decisions concerning two significant Alzheimer's drugs.
A critical aspect of this reexamination involves assessing whether the full impact of dementia on individuals providing unpaid care was adequately considered. Chris Bane, 51, has personally experienced this, having supported his mother Shirley, 77, since her Alzheimer's diagnosis ten years ago.
